Fda grants revascor® (rexlemestrocel-l) regenerative medicine advanced therapy (rmat) designation in children with congenital heart disease

Earlier this year fda granted revascor both rare pediatric disease designation (rpdd) and orphan-drug designation (odd) for congenital heart disease earlier this year fda granted revascor both rare pediatric disease designation (rpdd) and orphan-drug designation (odd) for congenital heart disease

MESO Ratings Summary

MESO Quant Ranking